TY - JOUR
TI - BCL-2, p53 and HLA-DR antigen expression in surgically treated parotid
cancer patients
AU - Genetzakis, Michael
AU - Gomatos, Ilias P.
AU - Georgiou, Anastasia N. and
AU - Giotakis, John
AU - Manolopoulos, Leonidas
AU - Papadimitriou,
AU - Isonstantina
AU - Chra, Helen
AU - Leandros, Emmanuel
AU - Tsigris,
AU - Christos
AU - Ferekidis, Eleutherios A.
JO - European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS)
PY - 2009
VL - 266
TODO - 3
SP - 417-424
PB - Springer-Verlag
SN - 0937-4477, 1434-4726
TODO - 10.1007/s00405-008-0754-1
TODO - Bcl-2; HLA-DR; p53; Parotid cancer; Prognosis
TODO - Our objective was to investigate the prognostic significance of bcl-2
protein, p53 protein and HLA-DR antigen expression in a group of
surgically treated parotid cancer patients. We studied bcl-2, p53 and
HLA-DR immunohistochemical expression in paraffin-embedded surgically
removed tissue specimens derived from 26 patients with parotid cancer
and 9 patients with Warthin parotid tumors operated between 2000 and
2006 at the Hippokration Hospital of Athens. The staining results were
correlated with the patients’ clinicopathological characteristics and
clinical outcome. Bcl-2 expression was associated with a significantly
decreased survival in patients with advanced tumor stage (P = 0.04),
high grade lesions (P = 0.02), or cervical node involvement (P = 0.03).
Radiotherapy was associated with a significantly improved
recurrence-free survival among patients with negative tumor staining for
either bcl-2, or both HLA-DR and bcl-2 [HLA-DR(-)/Bcl-2(-)] (P = 0.04
for both comparisons). Classical clinicopathologic factors failed to
show prognostic value both in the univariate and the multivariate
analyses performed. Our results suggest that bcl-2 can be used to
identify locally advanced or histologically aggressive tumors with a
lower survival probability following the application of standard
treatment modalities. Furthermore, bcl-2(+) patients should be
considered for more aggressive adjuvant treatment protocols, since
conventional radiotherapy often fails to decrease relapse rates in this
setting of patients.
ER -